Targeting KRAS with INspire platform

Its aberrant activation leads to uncontrolled cell proliferation, evasion of apoptosis, and enhanced tumor cell survival. Targeting KRAS has been a major focus in cancer therapeutics, and recent advances in developing small molecule inhibitors hold promise for effective treatment strategies against KRAS-driven cancers. However, these therapies have been demonstrated to suffer from rapid development of resistance by tumors and drug toxicities. INspire offers a new Mechanism of Action (MoA) and by blocking protein-protein interactions and downstream KRAS signaling. INspire based therapies are expected to be less toxic due to the high specificity of biologics and should have reduced resistance by the tumors.